



**HAL**  
open science

**Crystal structure of N-(7-[2-(dimethylamino)ethyl]amino-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide**

Jean Guillon, David Montoir, Mathieu Marchivie, Muriel Duflos,  
Marc-Antoine Bazin

► **To cite this version:**

Jean Guillon, David Montoir, Mathieu Marchivie, Muriel Duflos, Marc-Antoine Bazin. Crystal structure of N-(7-[2-(dimethylamino)ethyl]amino-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide. X-Ray Structure Analysis Online, 2017, 33, pp.41-43. 10.2116/xraystruct.33.41 . hal-01612261

**HAL Id: hal-01612261**

**<https://hal.science/hal-01612261v1>**

Submitted on 29 Oct 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Crystal Structure of *N*-(7-[[2-(Dimethylamino)ethyl]amino]-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide

Jean GUILLON,<sup>\*†</sup> David MONTOIR,<sup>\*\*</sup> Mathieu MARCHIVIE,<sup>\*\*\*</sup> Muriel DUFLOS,<sup>\*\*</sup> and Marc-Antoine BAZIN<sup>\*\*</sup>

<sup>\*</sup>Université de Bordeaux, UFR des Sciences Pharmaceutiques, INSERM U1212/UMR CNRS 5320, Laboratoire ARNA, 146 rue Léo Saignat, F-33076 Bordeaux Cedex, France

<sup>\*\*</sup>Département de Chimie Thérapeutique, Université de Nantes, Nantes Atlantique Universités, EA1155-IICiMed, Institut de Recherche en Santé 2, 22 Boulevard Bénéoni Goullin, F-44200 Nantes, France

<sup>\*\*\*</sup>Université de Bordeaux, CNRS, ICMCB, UPR 9048, F-33600 Pessac, France

The X-ray crystal structure of *N*-(7-[[2-(dimethylamino)ethyl]amino]-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide, a potential anticancer agent targeting Hsp90, was established. It crystallizes in the triclinic space group *P*-1 with cell parameters  $a = 9.3554(4)\text{Å}$ ,  $b = 11.4450(5)\text{Å}$ ,  $c = 11.5629(4)\text{Å}$ ,  $\alpha = 87.140(2)$ ,  $\beta = 78.8070(19)$ ,  $\gamma = 69.2119(19)$ ,  $V = 1135.21(8)\text{Å}^3$  and  $Z = 2$ . The crystal structure was refined to final values of  $R1 = 0.0492$  and  $wR2 = 0.1386$ . An X-ray crystal structure analysis revealed that each molecule features intermolecular N-H...N hydrogen bonds to form dimers.

(Received April 4, 2017; Accepted April 14, 2017; Published on web July 10, 2017)

Naphthyridones are well-known heterocyclic building-blocks that have been attracting considerable attention due to their potential pharmaceutical interests. Especially, 1,8-naphthyridin-4(1*H*)-ones have been widely investigated as aza-heterocycles with a large family of fluoroquinolones antibiotics.<sup>1</sup> Moreover, substituted 1,6-naphthyridin-2(1*H*)-one compounds have shown many interesting biological activities as, for example, cardiotoxic drugs,<sup>2</sup> protein kinases inhibitors<sup>3</sup> or neuroprotective agents.<sup>4</sup>

Furthermore, due to this large range of biological applications we undertook to investigate the synthesis of functionalized 1,6-naphthyridin-2(1*H*)-ones<sup>5</sup> in order to propose a practical access to these heterocycles and find potential biological activities.

We report herein on the structural characterization of the *N*-(7-[[2-(dimethylamino)ethyl]amino]-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide (Fig. 1), a 1,6-naphthyridin-2(1*H*)-one derivative that has been described to display antiproliferative activity towards breast cancer cell lines.<sup>5</sup>




Fig. 1 Chemical structure of *N*-(7-[[2-(dimethylamino)ethyl]amino]-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide.

The title compound was synthesized by through regioselective palladium-catalyzed cross-coupling reactions. Pale-yellow crystals having dimensions of  $0.24 \times 0.13 \times 0.04\text{ mm}^3$  suitable for X-ray diffraction analysis were obtained by the slow crystallization from a dichloromethane-ethyl acetate solution at  $+20^\circ\text{C}$ . The molecular structure of the title compound is depicted in Fig. 2. Crystal and experimental data are given in Table 1.

Crystallographic data of this compound were collected at 200 K with a Bruker APEX II diffractometer using monochromatic Mo- $K\alpha$  radiation ( $\lambda = 0.71073\text{ Å}$ ). The collected data were reduced using SAINT software (SAINT, Bruker AXS Inc., Madison, Wisconsin, USA), and all reflections were used for unit-cell refinement. The crystal structure was solved by direct methods and successive Fourier difference syntheses with the SHELXS program.<sup>6</sup> Refinement of the crystal structure was performed on  $F^2$  by weighted anisotropic full-matrix least-squares methods using the SHELXL program.<sup>6</sup> An absorption correction was performed by semi-empirical methods using the




Fig. 2 Asymmetric unit ORTEP view of the crystal structure of the title compound with our numbering scheme. Displacement ellipsoids are drawn at the 30% probability level.

<sup>†</sup> To whom correspondence should be addressed.  
E-mail: jean.guillon@u-bordeaux.fr

SADABS program.<sup>7</sup> All parts of program were used within the OLEX2 package.<sup>8</sup> All non-H atoms were refined anisotropically, and the positions of the H atoms were deduced from the coordinates of the non-H atoms to which they are linked, confirmed by Fourier synthesis and treated according to the riding model during refinement. H atoms were included for structure factor calculations, but not refined.

The title compound crystallizes in the triclinic *P*-1 space group, and the asymmetric unit is constituted by one molecule of *N*-(7-([2-(dimethylamino)ethyl]amino)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide. In the title compound, all bond lengths and angles of the fused heterocyclic rings were found to be within the normal ranges by comparing with the earlier substituted naphthyridones.<sup>9,10</sup>

Table 1 Crystal and experimental data for the title compound

Chemical formula: C <sub>23</sub> H <sub>29</sub> N <sub>5</sub> O <sub>5</sub>
Formula weight: 455.51
<i>T</i> = 200(2)K
Crystal system: triclinic
Space group: <i>P</i> -1
<i>a</i> = 9.3554(4)Å
<i>b</i> = 11.4450(5)Å
<i>c</i> = 11.5629(4)Å
$\alpha$ = 87.140(2)
$\beta$ = 78.8070(19)
$\gamma$ = 69.2119(19)
<i>V</i> = 1135.21(8)Å <sup>3</sup>
<i>Z</i> = 2
<i>D</i> <sub>x</sub> = 1.333 Mg/m <sup>3</sup>
Radiation: Mo <i>K</i> α ( $\lambda$ = 0.71073 Å)
<i>F</i> (0 0 0) = 484
Crystal size = 0.24 × 0.13 × 0.04 mm <sup>3</sup>
No. of reflections collected = 27362
No. of independent reflections = 4641
No. of reflections used [ <i>I</i> > 2σ( <i>I</i> )] = 2859
2θ range for data collection: 5.594 to 52.742°
Data/Restraints/Parameters = 4641/0/343
Goodness-of-fit = 1.012
<i>R</i> indices [ <i>I</i> > 2σ( <i>I</i> )]: <i>R</i> 1 = 0.0492, <i>wR</i> 2 = 0.1175
<i>R</i> indices (all data): <i>R</i> 1 = 0.0915, <i>wR</i> 2 = 0.1386
(Δ/σ) <sub>max</sub> = 0.000
(Δρ) <sub>max</sub> = 0.276 Å <sup>-3</sup>
(Δρ) <sub>min</sub> = -0.207 Å <sup>-3</sup>
Structure determination: SHELXS <sup>6</sup>
Refinement: SHELXL <sup>6</sup>
CCDC deposition number: 1511241

The dimethylamino-ethyl group is disordered on two positions with 43 and 57% respective proportions.

Thus, the torsion angle N(4)–C(10)–C(11a)–N(5a) was found at 71.7(4)°, and the homologous torsion angle N(4)–C(10)–C(11b)–N(5b) was –82.5(8)° showing that the 2-(dimethylamino)-ethyl]amino chain is not fully extended.

The naphthyridine ring atoms (N2–C4) have a root-mean-square deviation of only 0.026 Å from their least-squares plane, and thus are approximately coplanar. The interplanar dihedral angle between the naphthyridine least-squares plane and that through the trimethoxyphenyl ring atoms (C14–C19) is 6.61(5)°. The torsion angle involving the N(2)–C(3) bond in the pyridine ring [C(3)–N(2)–C(4)–C(5)] is noticed at 2.9(3)°, while the torsion angle of the conjugated C(6)–C(2)–C(3)–O(2) is found at 176.76(18)°. In addition, the conjugated C(2)–C(6) double bond was noticed at 1.350(3)Å, in the same range as that observed at 1.363(4)Å in the molecule 7-amino-1,8-naphthyridin-2(1*H*)-one.<sup>10</sup>

Two of the three methoxy groups, O(3)–C(20) and O(5)–C(22), were also found in-plane of the benzene system, as usually observed in methoxy functionalized aromatic systems. Hence, the torsion angles, C<sub>arom</sub>–C<sub>arom</sub>–O–C<sub>methoxy</sub>, bearing these two methoxy group are noticed between –1.6(3) to 4.6(3)°, and between –174.51(19) to 178.51(17)°. These two methoxy groups lie close to the aromatic plane, while the third one is out of the aromatic plane (C18–C17–O4–C21 torsion angle = 87.8(3)°) probably due to steric reasons as already observed in

Table 2 Hydrogen-bonding geometry (Å, °)

D–H...A	H–A	D–A	D–H...A
N(4)–H(4)–N(3) <sup>a</sup>	2.155	3.033(3)	175.4

Symmetry code: *a* = (–*x*, 2–*y*, –*z*).

Table 3 π–π interactions (Å, °)

Plane 1	Plane 2	Angle <sup>a</sup>	Distance <sup>b</sup>	Shift <sup>c</sup>
C14–C15–C16–C17–C18–C19	(N2–C4–C5–C6–C2–C3) <sup>a</sup>	5.64(8)	3.967(1)	1.920(4)
N2–C4–C5–C6–C2–C3	(N2–C4–C5–C6–C2–C3) <sup>b</sup>	0.0	3.439(2)	0.898(3)

a. Angle between planes.

b. Centroid to centroid distance.

c. Shift distance.

Symmetry codes: *a* = (2–*x*, 1–*y*, –*z*); *b* = (1–*x*, 1–*y*, –*z*).




Fig. 3 View of the crystal packing of the title compound (a) along the *b* direction showing the hydrogen bonds and Van der Waals interactions network, and (b) along the 102 lattice direction showing the π-stacking interactions.

other aromatic systems functionalized with 3 methoxy groups. Moreover, the N-C and C-C distances within this six-membered pyridine ring of the naphthyridine are in the range of 1.319(3) to 1.351(3)Å, and of 1.386(3) to 1.403(3)Å, respectively; consistent with the aromatic character of the ring system.

In common with other naphthyridone-based molecules, the title compound contains a double bond, C(2)-C(6), which was noticed at 1.350(3)Å, in the same range as those observed in various naphthyridones.<sup>9,10</sup> The C(3)=O(2) bond was noticed at 1.230(2)Å, as typically observed for C<sub>sp2</sub>=O bonds in lactams.

Significant intermolecular N-H...N hydrogen bonds occur between the amino N(4) and N(3) of the pyridine moiety, leading to the formation of a supramolecular dimer (Table 2). The crystal-structure cohesion is then ensured by several Van der Waals interactions and  $\pi$ -stacking that connect the dimers together (Table 3). Van der Waals interactions involving the dimethylamino, the methoxy and the carbonyl moieties connect the dimers approximately in the *a* and *c* direction while  $\pi$ -stacking interaction between the *N*-methyl pyridine of the double aromatic ring and the trimethoxy-benzene system complete the intermolecular interactions in the crystal structure approximately in the *b* direction (Fig. 3).

## References

1. D. Sriram, P. Senthilkumar, M. Dinakaran, P. Yogeewari, A. China, and V. Nagaraja, *J. Med. Chem.*, **2007**, *50*, 6232.
2. B. Singh, G. Y. Leshar, K. C. Pluncket, E. D. Pagani, D. C. Bode, R. G. Bentley, M. J. Connell, L. T. Hamel, and P. J. Silver, *J. Med. Chem.*, **1992**, *35*, 4856.
3. S. R. Natarajan, L. Liu, M. Levorse, J. E. Thompson, E. A. O'Neill, S. J. O'Keefe, K. A. Vora, R. Cvetovich, J. Y. Chung, E. Carballo-Jane, and D. M. Visco, *Bioorg. Med. Chem. Lett.*, **2006**, *16*, 5468.
4. Y. Hatayama, T. Hashimoto, H. Kohayakawa, T. Kiyoshi, K. Nakamichi, T. Kinoshita, and N. Yoshida, *Neuroscience*, **2014**, *265*, 217.
5. D. Montoir, S. Barillé-Nion, A. Tonnerre, P. Juin, M. Duflos, and M.-A. Bazin, *Eur. J. Med. Chem.*, **2016**, *119*, 17.
6. G. M. Sheldrick, *Acta Crystallogr. Sect. A*, **2008**, *64*, 112.
7. G. M. Sheldrick, **1996**, *SADABS*, University of Göttingen, Germany.
8. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, and H. Puschmann, *J. Appl. Cryst.*, **2009**, *42*, 339.
9. M. H. Sherlock, J. J. Kaminski, W. C. Tom, J. F. Lee, S.-C. Wong, W. Kreutner, R. W. Bryant, and A. T. McPhail, *J. Med. Chem.*, **1988**, *31*, 2108.
10. Z. Li, *Acta Crystallogr. Sect. E*, **2011**, *67*, o2541.

---

1. D. Sriram, P. Senthilkumar, M. Dinakaran, P. Yogeewari,